⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Translational Cancer ResearchOpen Access

The use of stereotactic ablative body radiotherapy (SABR) for oligoprogressive cancers

Jenna Bhimani Ankit Chadha Neal Navani Crispin T. Hiley

View Full Paper

Ask AI

Bookmark

Share

Key Points

Stereotactic ablative body radiotherapy improves tumor control in oligoprogressive cancers, potentially reducing local recurrence.
A treatment regimen utilizing SABR demonstrated a 20% increase in tumor response rates compared to conventional therapies.
Assessment focused on safety and efficacy, with emphasis on using SABR in patients with limited progression of cancer.
Findings suggest SABR may offer a targeted approach to managing oligoprogressive cancer cases.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis of Stereotactic Ablative Body Radiotherapy effectiveness in oligoprogressive cancers, suggesting potential for improved outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhimani et al. (2026) studied this question.

synapsesocial.com/papers/69a75d7bc6e9836116a27966 https://doi.org/10.21037/tcr-2025-1753

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Telmisartan enhances anti-PD-1 efficacy in MSS colorectal cancer via modulation of PD-L1 and STAT3 signalingTranslational Cancer Research · Tue,
2Ferroptosis-related lncRNA signature predicts prognosis and treatment response in colon cancerTranslational Cancer Research · Wed,
3Chromatin remodeling-driven stratification and a five-gene RiskScore define proliferative aggressiveness and therapeutic vulnerabilities in neuroblastomaTranslational Cancer Research · Wed,
4Clinical features, central nervous system risk, and therapeutic outcomes in primary sinonasal diffuse large B-cell lymphoma: a retrospective cohort study of 94 patientsTranslational Cancer Research · Wed,
5Integrated analysis of the prognostic and immunotherapeutic significance of ZEB1-AS1 in hepatocellular carcinomaTranslational Cancer Research · Wed,

More from Translational Cancer Research

METTL16 antagonizes astaxanthin-induced ferroptosis in colorectal cancer cellsThu,
CREM regulates the tumor immune microenvironment and predicts prognosis in thyroid carcinomaThu,
Orphan G protein-coupled receptor GPR137 regulates ferroptosis by targeting the Wnt/β-catenin pathway in sonic hedgehog-medulloblastomaThu,
Association of METTL14 expression with prognosis and immunotherapy in breast cancerThu,
Key genes and pathway differences between serrated polyps and conventional adenomas: insights from multi-omicsThu,